Xiao Min Schebye, San Carlos, CA (US); Diana Yuhui Chen, San Francisco, CA (US); Andrew Rankin, Redwood City, CA (US); Xiaodi Deng, San Mateo, CA (US); Joseph Toth, Belmont, MA (US); Linda Liang, Mountain View, CA (US); Michelle Minhua Han, Piedmont, CA (US); Christine Bee, San Francisco, CA (US); Hong-An Truong, San Francisco, CA (US); Mark J. Selby, San Francisco, CA (US); Nils Lonberg, Woodside, CA (US); Guodong Chen, East Brunswick, NJ (US); Richard Y. Huang, Bridgewater, NJ (US); Ekaterina G. Deyanova, Lawrenceville, NJ (US); and Alan J. Korman, Piedmont, CA (US)
Assigned to Five Prime Therapeutics, Inc., Thousand Oaks, CA (US); and Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Five Prime Therapeutics, Inc., Thousand Oaks, CA (US); and Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Jun. 21, 2022, as Appl. No. 17/845,742.
Application 17/845,742 is a division of application No. 16/506,754, filed on Jul. 9, 2019, granted, now 11,401,328.
Application 16/506,754 is a continuation of application No. PCT/US2019/040820, filed on Jul. 8, 2019.
Claims priority of provisional application 62/744,611, filed on Oct. 11, 2018.
Claims priority of provisional application 62/695,600, filed on Jul. 9, 2018.
Prior Publication US 2023/0174647 A1, Jun. 8, 2023
1. A nucleic acid comprising a polynucleotide sequence that encodes an antibody that specifically binds to human ILT4 (hILT4), the antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region (VH) comprising VH complementary determining region 1 (CDR1), CDR2 and CDR3 comprising the amino acid sequences of SEQ ID Nos: 155, 156, and 157, respectively, and wherein the light chain comprises a light chain variable region (VL) comprising VL CDR1, CDR2 and CDR3 comprising the amino acid sequences of SEQ ID Nos: 158, 159, and 160, respectively.